DDX39B抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using DDX39B mouse mAb against HepG2 (1), HepG2 (2), K562 (3), Jurkat (4), NIH/3T3 (5), MCF-7 (6), Jurkat (7), and Hek293 (8) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using DDX39B mouse mAb. Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using DDX39B mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human HeLa tissues using DDX39B mouse mAb with DAB staining.    

  
  

DDX39B (DEAD-box helicase 39B), also known as BAT1 or URH-49. is an ATP-dependent RNA helicase belonging to the DEAD-box protein family. It plays a critical role in mRNA processing, including splicing, nuclear export, and translation, by remodeling RNA secondary structures. DDX39B is involved in resolving RNA:RNA and RNA:protein interactions, ensuring efficient gene expression. Its function is closely linked to cellular processes such as proliferation, differentiation, and stress responses.

Antibodies targeting DDX39B are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunofluorescence, immunoprecipitation, and immunohistochemistry. These antibodies help researchers investigate DDX39B's role in diseases, particularly cancer and neurodegenerative disorders. For example, altered DDX39B expression has been associated with colorectal cancer, glioblastoma, and amyotrophic lateral sclerosis (ALS), suggesting its potential as a therapeutic target or biomarker.

Most DDX39B antibodies are raised against specific epitopes within its conserved helicase domains (e.g., amino acids 100-200 or 400-500), often in rabbits or mice. Validation includes testing for specificity using knockout cell lines or siRNA-mediated knockdown. Commercial antibodies typically provide data on cross-reactivity and recommended applications. Research on DDX39B continues to expand, driven by its emerging roles in RNA metabolism and disease pathogenesis, making reliable antibodies crucial for advancing these studies.